rifampicin-resistant TB (RR-TB)

High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa

Author
Kamban Hirasen, Rebecca Berhanu, Denise Evans, Sydney Rosen, Ian Sanne, Lawrence Long
Treatment success rates of rifampicin resistant (RR)/multi-drug resistant (MDR) tuberculosis (TB) in South Africa range from 43–48%, falling short of the World Health Organization’s target of ≥75%. We present rates and assess predictors of attrition by 12 months on treatment.
Include in home page features rotation
Off

High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?

Is the resource available on the Internet?
Yes
Author
Romain Ragonnet, James M. Trauer, Justin T. Denholm, Ben J. Marais and Emma S. McBryde

Globally 3.9% of new and 21% of re-treatment tuberculosis (TB) cases are multidrug-resistant or rifampicin-resistant (MDR/RR), which is often interpreted as evidence that drug resistance results mainly from poor treatment adherence. This study aims to assess the respective contributions of the different causal pathways leading to MDR/RR-TB at re-treatment.

Include in home page features rotation
Off
Subscribe to rifampicin-resistant TB (RR-TB)